Immunovant’s $75 Million Common Stock Offering

Cooley represented Immunovant, while Latham & Watkins represented the underwriters in the offering.Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people…